Delving into the Latest Updates on PUR-118 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action

modulators

Mechanism

Immunomodulators

Therapeutic Areas

Congenital DisordersDigestive System DisordersRespiratory Diseases+ [1]

Active Indication-

Inactive Indication

Cystic FibrosisPulmonary Disease, Chronic Obstructive

Originator Organization

Pulmatrix, Inc.

Active Organization-

Inactive Organization

Pulmatrix, Inc.

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to establish single and multiple dose safety in healthy subjects and subjects with mild chronic pulmonary obstructive disease (COPD). In addition, the study will evaluate preliminary proof of concept endpoints in COPD subjects such as biomarkers in sputum and mucociliary clearance.

Start Date01 Feb 2011

Sponsor / Collaborator

Pulmatrix, Inc.

[+1]

100 Clinical Results associated with PUR-118

Login to view more data

100 Translational Medicine associated with PUR-118

Login to view more data

100 Patents (Medical) associated with PUR-118

Login to view more data

1

Literatures (Medical) associated with PUR-118

01 Dec 2015·BMC Pharmacology and ToxicologyQ4 · MEDICINE

Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial

Q4 · MEDICINE

ArticleOA

Author: Kane, K ; Rosano, M ; Biller, H ; Mueller, M ; Hanrahan, J ; Holz, Olaf ; Hava, D L ; Hohlfeld, J M

BACKGROUNDThe ozone challenge model can be used to assess the efficacy of anti-inflammatory compounds in early phases of clinical drug development. PUR118, a calcium salt based formulation engineered in the iSPERSE(TM) dry powder delivery technology, is a novel anti-inflammatory drug for COPD. Here we evaluated the efficacy and safety of three doses of PUR118 in attenuating ozone-induced airway inflammation in healthy volunteers.METHODSIn a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.RESULTSSputum neutrophils, sputum CD14+ cells, as well as concentrations of IL1B, IL6, IL8, MMP9, and TNFA in sputum supernatant significantly increased after ozone exposure (n = 24). The percentage of sputum neutrophils (n = 12 who completed all treatments) did not change following treatment with different doses of PUR118. The high dose treatment group (n = 16) showed a decrease in the percentage and number of sputum macrophages (p ≤ 0.05) as well as a decrease in blood neutrophils (p = 0.04), and an increase in blood CD14 + cells (p = 0.04) compared to baseline. All dosages of PUR118 were safe and well tolerated.CONCLUSIONOzone challenge resulted in the expected and significant increase of sputum inflammatory parameters. Treatment with multiple rising doses of PUR118 was safe and three applications within 25 h prior to the ozone challenge had small effects on ozone-induced airway inflammation.TRIAL REGISTRATIONClinicalTrials.gov: NCT01690949. Registered 12 September 2012.

100 Deals associated with PUR-118

Login to view more data